

# Timothy Devos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5689053/publications.pdf>

Version: 2024-02-01

79  
papers

1,918  
citations

394421

19  
h-index

265206

42  
g-index

84  
all docs

84  
docs citations

84  
times ranked

2528  
citing authors

#	ARTICLE	IF	CITATIONS
1	SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-naïve Patients With Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3844-3850.	1.6	243
2	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. <i>Leukemia</i> , 2017, 31, 2726-2731.	7.2	242
3	KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. <i>Leukemia</i> , 2009, 23, 492-500.	7.2	236
4	Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. <i>Lancet Oncology</i> , The, 2017, 18, 88-99.	10.7	205
5	G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells. <i>Clinical Immunology</i> , 2012, 143, 83-87.	3.2	95
6	Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase 1 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 720-728.	2.0	56
7	Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. <i>Annals of Hematology</i> , 2018, 97, 1591-1600.	1.8	53
8	Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. <i>British Journal of Haematology</i> , 2021, 192, 1100-1105.	2.5	51
9	Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. <i>Haematologica</i> , 2015, 100, 893-897.	3.5	49
10	Driver mutations'™ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. <i>Leukemia</i> , 2017, 31, 970-973.	7.2	41
11	Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. <i>European Respiratory Journal</i> , 2022, 59, 2101724.	6.7	38
12	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2022, 5, e2147331.	5.9	38
13	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. <i>Haematologica</i> , 2018, 103, e392-e394.	3.5	31
14	Subset characterization of myeloid-derived suppressor cells arising during induction of BM chimerism in mice. <i>Bone Marrow Transplantation</i> , 2012, 47, 985-992.	2.4	29
15	Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene. <i>Haematologica</i> , 2017, 102, 1605-1616.	3.5	29
16	Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel. <i>European Journal of Haematology</i> , 2018, 101, 737-749.	2.2	27
17	One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096613.	2.5	24
18	Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. <i>Hematology</i> , 2018, 23, 785-792.	1.5	23

#	ARTICLE	IF	CITATIONS
19	Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. <i>EBioMedicine</i> , 2021, 66, 103288.	6.1	21
20	Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Na <sup>+</sup> -ve Myelofibrosis Patients. <i>Blood</i> , 2019, 134, 4164-4164.	1.4	21
21	Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. <i>European Journal of Haematology</i> , 2022, 109, 205-214.	2.2	19
22	Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. <i>Lancet Haematology</i> , 2022, 9, e480-e492.	4.6	18
23	A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. <i>Trials</i> , 2020, 21, 981.	1.6	17
24	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. <i>Cancer Medicine</i> , 2019, 8, 4089-4092.	2.8	16
25	Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases. <i>Microorganisms</i> , 2020, 8, 1733.	3.6	16
26	The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study. <i>Clinical Biochemistry</i> , 2017, 50, 452-454.	1.9	15
27	Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice—data from a Belgian registry. <i>Annals of Hematology</i> , 2021, 100, 1723-1732.	1.8	15
28	Pathogenesis of Autoimmunity After Xenogeneic Thymus Transplantation. <i>Journal of Immunology</i> , 2003, 170, 5936-5946.	0.8	14
29	Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis. <i>Annals of Hematology</i> , 2019, 98, 1421-1426.	1.8	14
30	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. <i>Leukemia Research</i> , 2018, 69, 100-102.	0.8	13
31	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. <i>Blood Cancer Journal</i> , 2018, 8, 89.	6.2	13
32	Long-term follow-up in a patient with the dermatoneuro syndrome treated with high-dose melphalan, thalidomide, and intravenous immunoglobulins for more than 7 years. <i>Annals of Hematology</i> , 2014, 93, 1927-1928.	1.8	12
33	Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. <i>Blood Advances</i> , 2022, 6, 5171-5183.	5.2	12
34	Treatment with lenalidomide (Revlimid <sup>®</sup> ), cyclophosphamide (Endoxan <sup>®</sup> ) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study. <i>Acta Clinica Belgica</i> , 2014, 69, 98-103.	1.2	10
35	Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. <i>Leukemia</i> , 2021, 35, 1197-1202.	7.2	9
36	Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. <i>Blood</i> , 2014, 124, 1824-1824.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Occurrence of Autoimmunity After Xenothymus Transplantation in T-Cell-Deficient Mice Depends on the Thymus Transplant Technique. <i>Transplantation</i> , 2008, 85, 640-644.	1.0	8
38	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. <i>American Journal of Hematology</i> , 2020, 95, E1-E3.	4.1	8
39	Momelotinib reduces transfusion requirements in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2022, 63, 1718-1722.	1.3	8
40	Myelofibrosis patients in Belgium: disease characteristics. <i>Acta Clinica Belgica</i> , 2015, 70, 105-111.	1.2	7
41	Multipotent mesenchymal stromal cells in kidney transplant recipients: The next big thing?. <i>Blood Reviews</i> , 2021, 45, 100718.	5.7	7
42	Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium. <i>Acta Haematologica</i> , 2019, 142, 197-207.	1.4	6
43	Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis. <i>Hematology</i> , 2022, 27, 23-31.	1.5	6
44	Screening of <i><sc>JAK</sc>2</i> V617F and <i><sc>MPL</sc> W515 K/L</i> negative essential thrombocythaemia patients for mutations in <i><sc>SESN</sc>2</i>, <i><sc>DNAJC</sc>17</i>, <i><sc>ST</sc>13</i>, <i><sc>TOP</sc>1</i> <i><sc>MT</sc></i>, <i><sc>NTRK</sc>1</i>. <i>British Journal of Haematology</i> , 2014, 165, 734-737.	2.5	5
45	Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey. <i>European Journal of Haematology</i> , 2018, 100, 361-366.	2.2	5
46	Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. <i>Leukemia and Lymphoma</i> , 2019, 60, 3493-3502.	1.3	5
47	Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Na <sup>+</sup> ve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib. <i>Blood</i> , 2019, 134, 1663-1663.	1.4	5
48	Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study. <i>Blood</i> , 2020, 136, 40-41.	1.4	5
49	Role of CD4+ and CD8+ T cells in the rejection of heart or islet xenografts in recipients with xenotolerance in the innate immune compartment. <i>Transplantation Proceedings</i> , 2005, 37, 516-517.	0.6	4
50	Late CD8+ T Cell-Dependent Xenoantibody Production in Innate Tolerant Nude Rats After Hamster Islet Grafting But Not After Hamster Heart Grafting. <i>Transplantation</i> , 2008, 85, 1489-1495.	1.0	4
51	Diagnosing nocturnal paroxysmal hemoglobinuria: a singleâ€center 4â€year experience. <i>International Journal of Laboratory Hematology</i> , 2017, 39, 329-336.	1.3	4
52	A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). <i>Blood</i> , 2014, 124, 1826-1826.	1.4	4
53	Predictors for Improvement in Patient-Reported Outcomes: <i>Post-Hoc</i> Analysis of a Phase 3 Randomized, Open-Label Study of Eculizumab and Ravulizumab in Complement Inhibitor-Na <sup>+</sup> ve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2021, 138, 2196-2196.	1.4	4
54	Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multi-center phase II trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 470-473.	1.3	3

#	ARTICLE	IF	CITATIONS
55	A haemovigilance team provides both significant financial and quality benefits in a University Hospital. <i>Transfusion and Apheresis Science</i> , 2017, 56, 199-205.	1.0	3
56	Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available. <i>Blood</i> , 2018, 132, 1774-1774.	1.4	3
57	Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry. <i>Blood</i> , 2018, 132, 1744-1744.	1.4	3
58	Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study. <i>Blood</i> , 2018, 132, 1754-1754.	1.4	3
59	Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry. <i>Blood</i> , 2019, 134, 4161-4161.	1.4	3
60	Bone healing with bortezomib-based regimens in multiple myeloma: a retrospective imaging study. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 387-394.	1.6	2
61	Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. <i>Hematology</i> , 2018, 23, 194-200.	1.5	2
62	Recanalization of portal axis after cavoportal hemitransposition in a liver transplant recipient with complete splanchnic thrombosis. <i>Pediatric Transplantation</i> , 2021, 25, e14097.	1.0	2
63	Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU). <i>Blood</i> , 2015, 126, 2807-2807.	1.4	2
64	A surprising cause of polycythaemia. <i>Thorax</i> , 2016, 71, 967-968.	5.6	1
65	Itraconazole for COVID-19: Preclinical Studies and a Proof-of-Concept Pilot Clinical Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
66	KIR-Ligand Incompatibility in the Graft-Versus-Host Direction Is Associated with Better Outcomes after Unrelated Cord Blood Stem Cell Transplantation for Acute Leukemia in Complete Remission. <i>Blood</i> , 2008, 112, 156-156.	1.4	1
67	MPL p.S204P Is a Recurrent Mutation in Essential Thrombocythemia. <i>Blood</i> , 2015, 126, 2837-2837.	1.4	1
68	Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry. <i>Blood</i> , 2020, 136, 6-8.	1.4	1
69	Post-cryopreservation viability of mesenchymal stem cells. <i>Cytotherapy</i> , 2014, 16, S83.	0.7	0
70	Improvement of transfusion practice and reduction in red blood cell utilization in Belgian hospitals: Results of a national survey and benchmarking. <i>Vox Sanguinis</i> , 2021, , .	1.5	0
71	Serial Serum Cytokine Measurement in a Patient with Systemic Scleromyxedema.. <i>Blood</i> , 2007, 110, 5100-5100.	1.4	0
72	JAK2 V617F-Negative and MPL W515K/L-Negative Essential Thrombocythemia: A High Resolution SNP Array Study. <i>Blood</i> , 2013, 122, 5258-5258.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Screening JAK2 V617F-Negative and MPL W515K/L-Negative Essential Thrombocythemia Patients For Mutations In SESN2, DNAJC17, ST13, TOP1MT, and NTRK1. Blood, 2013, 122, 5264-5264.	1.4	0
74	Analysis of Genotype, Phenotype and Outcome in a Belgian Cohort of Essential Thrombocythemia. Blood, 2014, 124, 5584-5584.	1.4	0
75	Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide. Blood, 2018, 132, 3037-3037.	1.4	0
76	Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. Blood, 2018, 132, 3039-3039.	1.4	0
77	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. Blood, 2019, 134, 2946-2946.	1.4	0
78	Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly. Blood, 2021, 138, 2576-2576.	1.4	0
79	An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis. Blood, 2020, 136, 8-10.	1.4	0